(redirected from RV1)

rotavirus vaccine, live, oral

(ro-ta-vye-russ vak-seen) ,


(trade name),


(trade name)


Therapeutic: vaccines immunizing agents
Pharmacologic: active immunizer
Pregnancy Category: C


Prevention of rotavirus gastroenteritis in infants.


Live attenuated vaccine replicates in the small intestine and produces immunity.

Therapeutic effects

Prevention of rotavirus gastroenteritis and its sequelae.


Absorption: Unknown.
Distribution: Remains in GI tract.
Metabolism and Excretion: Excreted in feces.
Half-life: Unknown.

Time/action profile



Contraindicated in: Hypersensitivity; History of intussusception; Severe combined immunodeficiency disease.
Use Cautiously in: Acute diarrhea or vomiting (delay immunization); Chronic gastrointestinal disorders (safety and efficacy not established); Febrile illness; Immunosuppression due to disease (including HIV), concurrent immunosuppressive drug therapy, malignant neoplasms affecting bone marrow/lymphatic system, or receipt of blood transfusion or blood products (including immunoglobulins) (safety and effectiveness not established).

Adverse Reactions/Side Effects


  • cough

Ear, Eye, Nose, Throat

  • runny nose


  • Intussusception (life-threatening)
  • flatulence
  • loss of appetite
  • rotavirus shedding in stool
  • vomiting


  • fussiness/irritability


Drug-Drug interaction

Concurrent immunosuppressants, antineoplastics, corticosteroids or radiation therapy may ↓ antibody response and ↑ risk of adverse reactions.



Oral (Infants 6–24 wk) 2 dose series; first dose at 6 weeks of age, followed at least 4 weeks later with a second dose; series should be completed by 24 weeks of age.


Oral (Infants 6–32wk) 3 dose series; first dose at 6–12 weeks of age, followed by the 2nd and 3rd doses at 4–10 week intervals; series should be completed by 32 weeks of age.


Powder for oral suspension (Rotarix) (requires reconstitution): 1 mL prefilled oral applicator (applicator contains latex)
Oral solution (Rotateq): 2 mL prefilled dosing tube

Nursing implications

Nursing assessment

  • Determine current health status and previous vaccination history of infant, including any reactions to previous dose of rotavirus vaccine. Delay administration in infants with acute diarrhea and vomiting.

Potential Nursing Diagnoses

Risk for infection (Indications)


  • May be administered with food or liquid, including breast milk, either before or after vaccination.
  • Oral: For Rotarix: Remove vial cap and push transfer adaptor into vial. Shake diluent in oral applicator (white, turbid suspension); push plunger of oral applicator to transfer diluent into vial. Reconstitute only with accompanying diluent. Do not mix with other vaccines or solutions. Do not administer if vial has cracks. Withdraw vaccine in oral applicator and twist to remove oral applicator. Do not use a needle; not for injection Vials of vaccine may be stored in the refrigerator and diluent may be stored at room temperature. Do not freeze. Administer within 24 hr of reconstitution. Discard in biological waste container if not used within 24 hrs.
    • If infant spits out or regurgitates most of dose, single replacement dose may be considered at same vaccination visit.
  • For RotaTeq: Open the dosing tube and puncture dispensing tip by screwing cap clockwise until it becomes tight. Administer dose by gently squeezing liquid into infant's mouth toward the inner cheek until dosing tube is empty. A residual drop may remain in the tip of the tube.
    • If infant spits out or regurgitates most of dose, a replacement dose is not recommended. The infant should continue to receive any remaining doses in the recommended series.

Patient/Family Teaching

  • Instruct parents or guardians to read Patient Information before first dose and prior to second dose and ask any questions they may have during the visit. Provide parent or guardian with the Vaccine Information Statements available at Emphasize the importance of completing the immunization series.
  • Advise parent to contact health care professional immediately if signs of intussusception (vomiting, diarrhea, severe stomach pain, severe crying, blood in the stool, or change in bowel movements) occur even if it has been several months since last vaccine dose.

Evaluation/Desired Outcomes

  • Prevention of rotavirus gastroenteritis and its sequelae.




Human live, oral rotavirus vaccine, monovalent.
References in periodicals archive ?
The extended interviews defined geographic locations to street level, and it was determined that RV1 was used for multidenominational worship and therefore was recognized by different names.
What's new: There are now two approved vaccines, RV5 and RV1, both live oral vaccines and about 74-87% effective at preventing the disease.
In January we started operating hydrogen fuel cell buses on route RV1 in London.
East London: 58, 67, 91, 150, 165, 179, 191, 193, 212, 215, 231, 236, 252, 259, 299, 308, 309, 323, 339, 341, 357, 365, 385, 389, 399, 476, 488, 498, D6, D7, D8, RV1, W6, W10, W11, W12
Adrian was readmitted to the RV1 on December 13, after his health took a turn for the worse.
There are hydrogen fuel cell motors already in operation in Canada, the USA and other countries and, notably, on London's RV1 bus route.
I commend to everyone a journey on bus number RV1 which travels from Covent Garden to Tower Bridge in London.
Risk Values Ltd, part of The Anti Money Laundering Network, has launched RV1 v2 for obtaining the personal profiles of an organisation's potential customers.
Adrian was readmitted to the RV1 on December 13 after his health took a turn for the worse.
Because RV1 coverage was extremely low during the study period, children who received RV1 also were excluded from the vaccine effectiveness analysis.
East London 58, 67, 91, 150, 165, 179, 191, 193, 212, 215, 231, 236, 252, 259, 299, 308, 309, 323, 339, 341, 357, 365, 385, 389, 399, 476, 488, 498, D6, D7, D8, RV1, W6, W10, W11, W12 West London 9(heritage service only), 10, 18, 23, 28, 31, 79, 83, 92, 95, 105, 187, 207,223, 224, 226, 228, 245, 282, 295, 328, 331, 414, 427, 487, 607, A10, E1, E3, E5, E7, E9, E10, PR2, U1, U2, U3, U4, U5, U10
Morningstar Credit Ratings issued Clear Capital its highest Residential Vendor Ranking, MOR RV1.